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Abstract
Background
MIGS have been developed as a surgical alternative for glaucomatous patients.
Purpose
To analyze the change in intraocular pressure (IOP) and glaucoma medications using differ-
ent MIGS devices (Trabectome, iStent, Excimer Laser Trabeculotomy (ELT), iStent Supra,
CyPass, XEN, Hydrus, Fugo Blade, Ab interno canaloplasty, Goniscopy-assisted translum-
inal trabeculotomy) as a solo procedure or in association with phacoemulsification.
Methods
Randomized control trials (RCT) and non-RCT (non randomized comparative studies, NRS,
and before-after studies) were included. Studies with at least one year of follow-up in
patients affected by primary open angle glaucoma, pseudoexfoliative glaucoma or pigmen-
tary glaucoma were considered. Risk of Bias assessment was performed using the
Cochrane Risk of Bias and the ROBINS-I tools. The main outcome was the effect of MIGS
devices compared to medical therapy, cataract surgery, other glaucoma surgeries and
other MIGS on both IOP and use of glaucoma medications 12 months after surgery. Out-
comes measures were the mean difference in the change of IOP and glaucoma medication
compared to baseline at one and two years and all ocular adverse events. The current
meta-analysis is registered on PROSPERO (reference n˚ CRD42016037280).
Results
Over a total of 3,069 studies, nine RCT and 21 case series with a total of 2.928 eyes were
included. Main concerns about risk of bias in RCTs were lack of blinding, allocation conceal-
ment and attrition bias while in non-RCTs they were represented by patients’ selection,
masking of participants and co-intervention management. Limited evidence was found
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based on both RCTs and non RCTs that compared MIGS surgery with medical therapy or
other MIGS. In before-after series, MIGS surgery seemed effective in lowering both IOP and
glaucoma drug use. MIGS showed a good safety profile: IOP spikes were the most frequent
complications and no cases of infection or BCVA loss due to glaucoma were reported.
Conclusions
Although MIGS seem efficient in the reduction of the IOP and glaucoma medication and
show good safety profile, this evidence is mainly derived from non-comparative studies and
further, good quality RCTs are warranted.
Introduction
Glaucoma is the second commonest cause of blindness worldwide [1]. To date, the main treat-
ment for preventing glaucomatous damage consists in lowering intraocular pressure (IOP)[2].
The first ocular hypotensive approach is commonly eye-drop medications, whose instillation
is often needed more than once per day. Poor compliance [3–4] and tolerability [5–6] can
sometimes lead to treatment failure. Ab externo filtration surgery is still considered the gold
standard but it is reserved to progressive disease and may lead to significant complications
[7,8]. Minimally-invasive glaucoma surgeries (MIGS) have been developed as safer and less
traumatic surgical interventions for patients with mild to moderate glaucoma or who are intol-
erant to standard medical therapy [9]. According to the commonly accepted definition, MIGS
are surgical procedures with an ab-interno approach, minimal trauma with very little or no
scleral dissection, minimal or no conjunctival manipulation, good safety profile and rapid
recovery [10].
MIGS devices can be divided in: trabecular, suprachoroidal and subconjunctival based [11].
They can be performed in association with cataract surgery or as a solo procedure [12].
The trabecular based devices work by improving trabecular outflow through Schlemm’s
canal. The suprachoroidal based devices improve the uveoscleral outflow through a connection
between the anterior chamber and the suprachoroidal space while the subconjunctival devices
create an alternative outflow pathway of the aqueous humor to the subconjunctival space
[13,14].
There is a growing interest about MIGS procedures and several clinical studies have been
published in the past years. This increase in surgical options should be supported by a clear
evidence of their efficacy, to give the surgeon a detailed panorama on the potential surgical
options.
However, many clinical studies have been small, nonrandomized, and often lacking appro-
priate control arms. Moreover, these studies often exhibit great variability in measured out-
comes, definition of success/failure and follow-up periods.
The purpose of the current meta-analysis is to analyze available data on MIGS and to sum-
marize and quantify their effect on both intraocular pressure and use of topical glaucoma med-
ications as well as their safety profile.
Materials and methods
In this research, we adhered to the Preferred Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.
MIGS: A systematic review and meta-analysis
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Protocol and registration
The current meta-analysis is registered on PROSPERO (reference n˚ CRD42016037280) and is
available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037280.
During the peer-review process, extensive changes were required to the original protocol.
Literature search strategy
The construction of search strategies was performed by an expert epidemiologist (MC) using
database specific subject headings and keywords. Electronic databases search was performed
by two clinicians (LD, CL) and a third member (AF) in case of disagreement. Articles pub-
lished between January 1, 2000 and December 31, 2016 were included.
Information sources included: MEDLINE Daily and MEDLINE (Ovid), MEDLINE In-Pro-
cess and Other Non-Indexed Citations, CENTRAL (which contains the Cochrane Eyes and
Vision Group Trials Register), EMBASE (Ovid), Latin American and Caribbean Literature on
Health Sciences (LILACS), CINAHL (EBSCO), Trip Database and The National Institute for
Health and Care Excellence (NICE). The search strategies for MEDLINE are included in the
supplementary material (S1 Appendix). These searches were supplemented by hand searching
the bibliographies of all the included studies. Grey literature was not considered in this meta-
analysis due to excessive lack of essential information that usually affects this type of research.
Study selection
Study design: Randomized controlled trials (RCT) and non-RCT (non-randomized compara-
tive studies, NRS, and before-after studies) were included. Accepted languages of publication
were: English, German, French, Spanish, Portuguese and Italian.
Exclusion criteria:
1. Follow-up shorter than 12 months.
2. Glaucoma types other than primary open angle glaucoma (POAG). pseudoexfoliative
(PEX) and pigmentary glaucoma (PG).
3. Number of patients lost at follow-up equal or greater than 15% (in non RCT studies)
4. Any previous glaucoma surgery except laser trabeculoplasty.
5. Studies including patients younger than 18 years.
Interventions:
In accordance with the provided definition of MIGS we included studies regarding:
• Ab interno trabeculotomy, Trabectome device (NeoMedix, Tustin, CA, USA)
• Trabecular Microbypass Stent (iStent, Glaukos, Laguna Hills, CA, USA)
• Schlemm’s Canal Scaffold (Hydrus, Ivantis, Irvine, CA, USA)
• Suprachoroidal Microstent (Cypass Transcend Medical, Menlo Park, CA, USA)
• iStent Supra (iStent, Glaukos, Laguna Hills, CA, USA)
• XEN Subconjuntival Implant gel stent (Aquesys, Aliso Viejo, CA, USA/ Allergan, Irvine,
CA, USA)
• Ab interno Canaloplasty (ABIC)
• Excimer Laser Trabeculotomy (ELT, Glautec AG, Nurnberg, Germany)
MIGS: A systematic review and meta-analysis
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• Gonioscopy-Assisted Transluminal Trabeculotomy (GATT)
• Fugo plasma blade (MediSurg Research and Management Corp., Norristown, PA, USA)
Studies about MIGS as a solo procedure or combined with cataract surgery were
considered.
Screening of titles and abstracts was carried out and not pertinent articles were rejected.
Full texts of residual articles were evaluated independently for eligibility. The process was
made according to the PRISMA flow diagram. Duplicates were removed using EPPI reviewer
(by EPPI-Center, Social Science Research Unit, the Institute of Education, the University of
London, UK).
Data collection and risk of bias assessment
The main outcome of this meta-analysis was the effect of MIGS devices compared to medical
therapy, cataract surgery, other glaucoma surgeries and other MIGS on the change in both
IOP and use of glaucoma medications 12 months after surgery. Outcomes were analyzed sepa-
rately for every MIGS, as well as for the solo and the combined procedures.
Secondary outcomes were:
• the effect of MIGS on the change in IOP and glaucoma medications between baseline and 12
and 24 months
• surgery-related adverse events.
The measure of effect was the mean change in IOP (mmHg) and the mean change in num-
ber of antiglaucoma medications, since change is expected to be less dependent of differences
in baseline values.
Data were collected from each study independently by two reviewers (LD, CL). In order to
obtain or confirm missing or uncertain data from investigators, corresponding Authors were
contacted twice by email. In case of impossibility to obtain missing/incomplete data from cor-
responding Authors, data were extrapolated from figures/graphics when available. Given the
potential inaccuracy of these data, outcomes were also analyzed separately excluding all
inferred-results-studies, as a sensitivity analysis.
The quality assessment was evaluated with the latest version of the risk of Bias tool recom-
mended in the Cochrane handbook for systematic review of Interventions (Chapter 8, Higgins
2011) [15] for RCT and the ROBINS-I checklist for non-RCT [16]. RCT studies were judged
for the selection bias, performance bias, detection bias, attrition bias, reporting bias and other
sources of bias.
Non RCT studies were judged for confounding bias, selection bias, bias in classification of
interventions, bias in deviation from intended interventions, bias due to missing data, bias in
measurement of outcome and bias in selection of the reported results. Results from ROBINS-I
were separately reported for NRS and before-after studies, considering that the use of
ROBINS-I in before-after studies is exploratory and has not been validated yet.
Studies were not excluded a priori based on quality reporting assessment.
Data synthesis and analysis
Data were analyzed from March to May 2017. Statistical analysis was performed using STATA
(software version 13.1, STATA corporation, College Station, TX, USA). The random effect
method was used to perform statistical analysis.
We presented mean and standard error (SE) of the IOP and number of glaucoma medica-
tion at baseline and endpoint were used to compute their mean reduction and mean and
MIGS: A systematic review and meta-analysis
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standard deviation of IOP percentage of reduction (IOPR %, SD-IOPR%):
IOPR ¼ IOPbaseline   IOPendpoint
IOPR% ¼
IOPR
IOPbaseline
SD   IOPR% ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðSEbaselineÞ
2
þ ðSEendpointÞ
2
q
IOPbaseline

ffiffiffi
n
p
(n: number of patients at the baseline).
When a meta-analysis was possible, summary effect measures were reported as weighted
mean difference [17,18]; when the SD of the mean change was not available, the following for-
mula was used to imputed it:
SDCHANGE ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2baseline þ SD2final   ð2  Corr  SDbaseline  SDfinalÞ
q
A correlation value (Corr) of 0.3 was used as it was the median value of the available SD
values.
To investigate heterogeneity among studies, I2 statistics were computed. Large statistical
heterogeneity was generally found, due to the large precision of estimates in this type of
matched studies and to the use of continuous outcomes [19]. We had planned to use funnel
plots were generated and both Egger’s [20] and Begg’s [21] tests to assess the risk of publication
bias but the limited number of studies did not allow this type of testing.
Results
Study selection
A total of 3,069 studied were screened using the described search strategy. At the end of the
selection process, 30 studies were identified [22–51]. 3 out of 30 studies compared Trabectome
with iStent surgery[22,23,25] while 2 out of 30 studies compared Trabectome combined and
solo procedures[26,27]. Analyzed studies included 9 RCTs (Trabectome = 0, iStent = 6,
CyPass = 1, Aquesys = 0, Hydrus = 1 and ELT = 1) and 21 non-RCTs (Trabectome = 7 (7
NRS), iStent = 11 (4 NRS, 7 before-after), CyPass = 1 (before-after), XEN = 1 (before-after),
Hydrus = 2 (2 NRS) and ELT = 2 (1 NRS, 1 before-after). The RCTs included 850 eyes while
2,078 eyes were included in the non RCTs studies (1,598 eyes in NRS, 480 eyes in before-after
studies). No studies regarding iStent Supra, ABIC, GATT and Fugo Blade met the eligibility
criteria. Overall there were 20 studies about combined procedures (1521 eyes) and 15 about
solo procedures (1407 eyes). Further details on included studies are given in the Prisma flow
diagram (Fig 1).
Excluded studies on the basis of full-text are referenced in the supplementary material (S2
Appendix).
Study characteristics
Baseline characteristics of included studies are reported in Table 1.
Tables 2 and 3 reported IOP and number of medications at baseline and 1-year follow-up
in different type of studies, together with their percent reduction.
In two studies [30,33] missing data were taken from previous papers by the same authors
[52,53], being the former the long-term follow-up studies.
MIGS: A systematic review and meta-analysis
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Baseline characteristics of included patients who were given indication for MIGS therapy
were highly variable in terms of glaucoma severity, IOP values (e.g medicated and unmedi-
cated) and number of glaucoma medications. The majority of studies reported visual field and
clinical parameters to describe the baseline glaucoma severity of patients. In all the studies but
three mild to moderate glaucoma were included, while in three papers advanced glaucoma
[25,34] (Mean Deviation -12 dB) and need for filtrating surgery were baseline findings [44].
Fig 1. PRISMA flow diagram a = number of studies excluded for device respected the same order as the
main boxes.
https://doi.org/10.1371/journal.pone.0183142.g001
MIGS: A systematic review and meta-analysis
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Medicated IOP had to be between 18 and 30 mmHg in some studies [e.g. 36, 37, 38, 40],
even though different thresholds were chosen by other authors (i.e. 14–30 mmHg [33], 17–31
mmHg [35], 21–35 mmHg [44],> 18 mmHg [25]). Some inclusion criteria considered as a
cutoff value the target IOP [e.g. 22,34].
Washed-out IOP values were even variable across studies, being for example 22–32 [33] or
22–38 mmHg [36, 37,38,39,40], but not all studies contemplate wash-out, mainly due to ethical
implications.
Only one study [41] included naïve patients, three studies [38,39,40] in the iStent as a solo
procedure group included patients on one hypotensive medication and POAG subjects on 2
topical therapy were considered eligible in the study by Ahmed [37].
Main outcomes at follow-up visit over one year are reported in Table 4.
Risk of bias
RCT. Risk of bias assessment for individual RCTs are reported in S1 Table, S1 and S2
Figs. In RCT studies greater risks were found in detection and in the attrition bias. Three
Table 3. IOP and antiglaucoma medication at baseline and one year in before-after studies.
Author, Year Device Eyes
(n)
IOP Baseline
(mmHg)
Mean ± SD
IOP 1 year
(mmHg)
Mean ± SD
IOP
Reduction
(%)
Mean ± SD
Medication
Baseline (n)
Mean ± SD
Medication
1 year (n)
Mean ± SD
Medication
Reduction (n)
ARRIOLA-VILLALOBOS,
201229
1 ISTENT
COMBINED
19 19.4 ± 1.9 17.3 ± 3.2a 11.0 ± 19.2 1.3 ± 0.5 0.2 ± 0.4 1.15
SPIEGELb, 200932 1 ISTENT
COMBINED
48 21.7 ± 4.0 17.4 ± 3.0 19.8 ± 23.5 1.6 ± 0.8 0.4 ± 0.6 1.20
ARRIOLA-VILLALOBOSc,
2016 33
2 ISTENT
(INJECT)
COMBINED
20 20.0 ± 3.7 16.8 ± 2.2 16.0 ± 21.7 1.3 ± 0.7 0.3 ± 0.6 1.00
BELOVAYd, 201234 2 ISTENT
COMBINED
28 17.3 ± 4.0 13.8 ± 3.4a 20.2 ± 30.4 2.8 ± 0.8 1.0 ± 1.3a 1.80
AHMED, 201437 2 ISTENT SOLO 39 22.2 ± 2 13.0 ± 2.4 41.4 ± 14.1 2.0 e ± 0 1.0 ± 0e 1.00e
DONNENFELD, 201538 2 ISTENT SOLO 39 20.6 ± 2 13.5f ± 1.8f 34.5 ± 13.3 1.0 e ± 0 NR N/A
LINDSTROM, 201640 2 ISTENT
(INJECT) SOLO
57 19.5 ± 1.5 14.2 ± 1.9 27.2 ± 12.4 1e ± 0 0 1.00
VOSKANYAN, 201442 2 ISTENT
(INJECT) SOLO
99 22.1 ± 3.3 15.7 ± 3.7 29.0 ± 23.2 2.2 ± 0.4 NR N/A
GARCI´A-FEIJOO, 201544 CYPASS SOLO 65 24.5 ± 2.8 16.4 ± 5.5 33.1 ± 27.0 2.2 ± 1.1 1.4 ± 1.3 0.80
PEREZ-TORREGROSA,
201645
XEN COMBINED 30 21.2 ± 3.4 15.0 ± 2.5 29.1 ± 19.8 3.1 ± 0.7 0.2 ± 0.7 2.90
TO¨ TEBERG-HARMS,
201349
ELT COMBINED 64 19.8 ± 5.3 15.2 ± 4.4 23.2 ± 34.8 2.4 ± 1.1 1.5 ± 1.4 0.90
Number rounded to the first decimal digit, (second decimal for medication reduction). If data discordance between text and tables, data from the text was
chosen. SD = standard deviation. IOP = intraocular pressure. NR = not reported. N/A = not applicable
a
= data inferred from graphics/figures.
b
= baseline data from per-protocol(PP) population (48 patients), 12-months IOP and medication on 42 patients (some patients excluded by the study due to
secondary surgery)
c
= 3 patients received only 1 iStent. SD 1 year from Arriola-Villalobos 201353
d
= considered as a before-after study as the 3-iStent group was excluded due to 8% mixed mechanism.
e
= medication use per protocol.
f
= calculated on 92.3% patients without medication.
https://doi.org/10.1371/journal.pone.0183142.t003
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studies were considered at high risk of attrition bias [31] and detection bias [36,41]. Unclear
risk of allocation concealment was observed in almost all studies, mainly due to incomplete
description. No masking of patients, surgeons and outcome assessors seems to be the main
concern among the analyzed studies, representing the most serious bias and potentially con-
founding the outcomes.
Funding by device industry or authors affiliations are often declared (7 out of 9 studies),
details are reported in S4 Table.
NRS. Risk of bias assessment for NRS are reported in S2 Table and S3 Fig.
A serious risk of confounding was observed in all studies except one that applied a propen-
sity score based on relevant baseline variables [48]. All other NRS were at serious risk of con-
founding bias due to a lack of baseline IOP and medication adjustment between groups. Some
studies recruited consecutive patients and were judged at low risk of bias in selection of partici-
pants; other authors excluded patients who did not complete the follow-up: these papers were
therefore judged at serious risk [22,23,28,47]. As MIGS and cataract surgery are well-defined
once only interventions, misclassification of interventions was unlikely. Glaucoma therapy was
the main cointervention, potentially causing serious performance bias. Probably due to the clin-
ical-setting of most NRS, glaucoma medications were often reintroduced or discontinued in the
follow-up at clinicians’ discretion (judged as serious risk). If glaucoma therapy was prescribed
basing on target IOP, studies were considered at moderate risk [24,28,48]. In our review, studies
presenting with more than 15% of patients lost at one-year follow-up were excluded to avoid as
much as possible a bias due to missing data. Thus, all included studies were judged at low risk.
Due to a lack in masking strategy, outcome assessment was judged at moderate risk of bias in all
studies. The method of outcome assessment was thought to be comparable across intervention
groups and the outcome measure was considered minimally influenced by the knowledge of
intervention. Selective reporting of subgroup of participants (e.g. patients receiving secondary
surgery) was observed in one study, evaluated as a serious reporting bias [22].
Before-after studies. We adapted the ROBINS-I for evaluating the risk of bias in before-
after studies, results are reported in S3 Table and S4 Fig.
All studies, even the MIGS arms RCT and NRS were considered as before-after studies. For
before-after studies confounding domain was not applicable as subjects were not assigned to
different groups. Seven out of 30 studies [24,25,30,33,48,50,51] recruited consecutive patients,
thus they were at low risk of bias in selection of participants; nine papers [22,23,26,27,28,34,38,
42,47] were judged at serious risk of selection bias because the exclusion of some eligible par-
ticipants was related to the outcome (e.g. exclusion of patients who did not complete the fol-
low-up or received secondary surgery). In some studies lack of information about selection of
participants could not permit risk assessment. Misclassification of assignment of intervention
did not occur in before-after study as for NRS: MIGS and cataract surgery are well-defined
once-only interventions.
Glaucoma therapy was the main cointervention, potentially causing serious performance
biases. Only studies which reported washed-out IOP both pre- and post-operatively were
judged to be at low risk [31,36,37,43,46]; other studies were considered at moderate risk if one
between pre and post-operative IOP measure was washed-out. Only one study reported mask-
ing strategy [43]. Risk of bias due to missing data, measurement of outcome and selection of
the reported results were similar to those of NRS.
Funding and authors affiliations for all studies are reported in S4 Table.
Outcomes in comparative studies
Outcomes are reported in Figs 2 and 3.
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MIGS devices versus cataract surgery. Five papers (all RCT) compared MIGS and cata-
ract surgery with cataract surgery alone on a total of 871 patients. CYPASS: one RCT [43] com-
pared combined Cypass surgery with cataract surgery alone on 505 patients. Unmedicated
Fig 2. Forest plot for comparison in IOP change between study arms at 12-months (divided by device and procedure). Values
expressed in Weighed Mean Difference (WMD).
https://doi.org/10.1371/journal.pone.0183142.g002
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IOP data were reported and showed at 1 year a mean change of 7.9 ± 4.1 mmHG and 6.2 ± 3.8
mmHg in the MIGS and control groups respectively. WMD was -1.7 (95% CI -2.47, -0.93) in
favor of Cypass surgery (Fig 2). The change in the number of glaucoma medication was
Fig 3. Forest plot for 12-months difference in change in number of glaucoma medications reduction (divided by device and procedure)
values expressed in Weighed Mean Difference (WMD).
https://doi.org/10.1371/journal.pone.0183142.g003
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1.2 ± 0.79 and 0.6 ± 0.95 in the MIGS and control group respectively. WMD was -0.6 (95% CI
-0.78, -0.42) in favor of Cypass surgery (Fig 3). The IOP lowering effect of the Cypass remained
stable over 2 years, as well as the glaucoma medication reduction (S5 and S6 Figs). Risk of bias
analysis showed unclear risk in four domains and low risk in two domains (S1 Table).
HYDRUS: one RCT [46] compared combined Hydrus surgery with cataract surgery alone
on 100 patients. Medicated IOP data were reported and showed at 1 year a mean change of
2.8 ± 3.7 mmHg and 2.6 ± 4 mmHg in the MIGS and control groups respectively. WMD was
-0.2 (95% CI -1.73, 1.33) in favor of Hydrus surgery (Fig 2). Unmedicated IOP data were
reported and showed at 1 year a mean change of 9.7 ± 4.5 mmHg and 9.2 ± 4.7 mmHg in the
MIGS and control groups respectively. WMD was -0.5 (95% CI -2.39, 1.39) in favor of Hydrus
surgery. The change in the number of glaucoma medication was 1.5 ± 1.07 and 1.2 ± 1.05 in
the MIGS and control group respectively (Fig 3). WMD was -0.3 (95% CI -0.72, 0.12) in favor
of Hydrus surgery. The IOP lowering effect of the Hydrus remained stable over 2 years, as well
as the glaucoma medication reduction (S5 and S6 Figs). These results suggest little difference
in IOP change between Hydrus surgery and cataract surgery. The study showed low risk of
bias in five domains (S1 Table).
ISTENT: three RCT [30,31,35] compared combined iStent surgery with cataract surgery
alone on 266 patients.
In the RCT by Craven [30], medicated IOP data were reported and showed at 1 year a
mean change of 1.6 ± 3 mmHg and 0.9 ± 3.3 mmHg in the MIGS and control groups respec-
tively. WMD was -0.7 (95% CI -1.58, 0.18) in favor of iStent surgery (Fig 2). The change in the
number of glaucoma medication was 1.4 ± 0.8 and 1.1 ± 0.8 in the MIGS and control group
respectively. WMD was -0.3 (95% CI -0.52, -0.08) in favor of iStent surgery (Fig 3). The IOP
lowering effect of the iStent remained stable over 2 years, as well as the glaucoma medication
reduction (S5 and S6 Figs). Risk of bias analysis showed unclear risk in four domains and low
risk in two domains (S1 Table).
In the RCT by Fea [31], medicated IOP data were reported and showed at 1 year a mean
change of 3.1 ± 2.6 mmHg and 1.1 ± 2.9 mmHg in the MIGS and control groups respectively.
WMD was -2.0 (95% CI -4.04, 0.04) in favor of iStent surgery. Unmedicated IOP data were
reported and showed at 1 year a mean change of—1.7 ± 2.8 mmHg and 1.7 ± 3.6 mmHg in the
MIGS and control groups respectively. WMD was -3.4 (95% CI -5.74, -1.06) in favor of iStent
surgery (Fig 2). The change in the number of glaucoma medication was 1.5 ± 0.8 and 0.8 ± 1 in
the MIGS and control group respectively. WMD was -0.7 (95% CI -1.35, -0.05) in favor of
iStent surgery (Fig 3). This study was at high risk of attrition bias and low or unclear risk of
other biases (S1 Table).
In the RCT by Ferna´ndez-Barrientos [35], IOP data were reported as unmedicated and
medicated values at baseline and 1 year after double iStent surgery respectively. The mean
change in IOP was 6.6 ± 3 mmHg and 3.8 ± 2.7 mmHg in the MIGS and control groups
respectively. WMD was -2.8 (95% CI -4.75, -0.85) in favor of iStent surgery (Fig 2). Risk of bias
analysis showed unclear risk in four domains and low risk in two domains (S1 Table).
Meta-analysis was performed considering the studies by Craven [30] and Fea [31], with
moderate heterogeneity (I2 = 24.3%). WMD was -1.01 (95% CI -2.1, 0.08); p = 0.07 suggesting
a small advantage of iStent compared to cataract surgery, but this estimate was imprecise and
the 95%CI included no difference.
MIGS devices versus medical therapy. Three studies (2 RCTs and 1 NRS, 335 patients
overall) compared MIGS (ELT and iStent as solo procedures) with standard medical therapy.
ELT: in the NRS by Babighian [50], ELT was compared to medical therapy that was carried-
on in fellow eyes, representing the control group. This study with a small sample size (21
patients) showed a large statistically significant IOP difference, WMD = -8.0 mmHg (95% CI
MIGS: A systematic review and meta-analysis
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-9.0, -7.0); IOP change was -8.6 ± 0.9 mmHg and -0.6 ± 2.2 mmHg in the ELT and medication
group, respectively (Fig 2). The study reported outcomes on the number of glaucoma medica-
tions at 2 years only, with a WMD of -1.53 (95% CI -1.96, -1.10) in the ELT group compared
to baseline values (S6 Fig). IOP changes at 2 years were similar to those at 12 months (S5 Fig).
This study was at high risk of bias in two domains of the tools (bias due to confounding, bias
due to deviation from intended intervention), S2 Table.
ISTENT: in the RCT by Fea [39] (94 eyes in the iStent group and 98 eyes in the medication
group) the medicated IOP change was 8.1 ± 2.6 mmHg in the 94 eyes with double iStent
implant and 7.5 ± 2.2 mmHg in the 98 eyes on medical therapy (beta-blocker and prostaglan-
din). The WMD was -0.60 (95% CI -1.29, 0.09) in favour to iStent surgery. Considering base-
line wash-out IOP values, IOP changes showed greater reduction in both groups: 12.2 ± 2.3
and 11.6 ± 2.2 in iStent and medication group respectively. The WMD did not show any differ-
ence, -0.60 (95% CI -1.25, 0.05) in favour to iStent surgery (Fig 2). Change analysis in number
of medications could not be performed because all patients were on one anti-glaucomatous
drug before randomization. Risk of bias analysis showed unclear risk in four domains and low
risk in two domains (S1 Table).
In the RCT by Vold [41] 54 naïve eyes were randomized to double iStent implantation and 47
eyes to medical therapy (prostaglandin). It emerged a greater IOP reduction in the iStent group
(11.8 ± 2.65 mmHg) than in the medication group (11.2 ± 4.4 mmHg), WMD = -0.60 (95%CI
-2.05, 0.85), Fig 2. Analysis on medication change was not conducted because of per-protocol use
of anti-glaucomatous medications. The study was at high risk of bias in one domain (S1 Table).
Meta-analysis was performed on these two studies. Implantation of 2 iStent caused a slightly
larger reduction in IOP compared to medical therapy, WMD = -0.60 (95% CI -1.23, 0.03), I-
squared = 0.0%, p = 0.060; however this benefit was modest and the 95% CI included no difference.
MIGS devices versus other glaucoma surgeries. Four papers (1 RCT, 3 NRS including 30
and 347 patients respectively) compared MIGS with other glaucoma surgeries. In three studies
(1 RCT and 2 NRS) MIGS were performed as solo procedures while in one NRS MIGS and its
comparator were performed together with cataract surgery.
ELT: one RCT [51] compared ELT surgery with SLT on 30 patients. Medicated IOP data
were reported and showed at 1 year a mean change of 9.0 ± 2.4 mmHg and 4.9 ± 1.8 mmHg in
the MIGS and control groups respectively. WMD was -4.1 (95% CI -5.62, -2.58) in favor of
ELT surgery (Fig 2). The change in the number of glaucoma medication was not reported at
one year. At two years after surgery the IOP change in the ELT group was slightly inferior than
it was after 12 months (S2 Fig). Glaucoma medication were reported at 2 years, with a WMD
of -1.54 (95% CI -2.05, -1.03) in the ELT group compared to baseline values. The study was at
low risk of bias in all domains but one which was judged unclear (S1 Table).
HYDRUS: one NRS [48] compared combined Hydrus surgery with SLT on 56 patients.
Medicated IOP data were reported and showed at 1 year a mean change of 6.6 ± 5.6 mmHg
and 7.3 ± 2.5 mmHg in the MIGS and SLT group respectively. WMD was 0.69 (95% CI -1.55,
2.93) in favor of SLT (Fig 2). The change in the number of glaucoma medication was 1.39 ±
0.97 and 0.48 ± 1.1 in the MIGS and SLT group respectively. WMD was -0.91 (95% CI -1.45,
-0.37) in favor of Hydrus surgery (Fig 3). The study was at moderate risk of bias in three
domains and at low risk in four domains (S3 Table).
TRABECTOME: one study (NRS) compared Trabectome and cataract surgery with trabec-
ular aspiration and cataract surgery on 55 patients [24]. In the study, medicated IOP data were
reported and showed at 1 year a mean change of 9.3 ± 5.6 mmHg and 5.1 ± 6.4 mmHg in the
MIGS and control groups respectively. WMD was -4.2 (95% CI -7.38, -1.02) in favor of Tra-
bectome combined surgery (Fig 2). The change in the number of glaucoma medication was
0.29 ± 1.0 and -0.08 ± 1.22 in the MIGS and control group respectively. WMD was -0.37 (95%
MIGS: A systematic review and meta-analysis
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CI -0.96, 0.22) in favor of Trabectome surgery (Fig 3). The study was at serious risk of bias in
one domain and at moderate and low risk in other domains (S2 Table).
One study (NRS) compared Trabectome surgery with a modified goniotomy technique on
49 PEX and 187 POAG patients [28]. Medicated IOP data on PEX patients were reported and
showed at 1 year a mean change of 9.7 ± 9.3 mmHg and 6.7 ± 7.4 mmHg in the MIGS and con-
trol groups respectively. WMD was -2.92 (95% CI -7.59, 1.75) in favor of Trabectome surgery.
Different results were reported in POAG patients where mean IOP change at 1 year was
4.6 ± 5.4 mmHg and 5.8 ± 7.0 mmHg in the MIGS and control groups respectively. WMD was
1.24 (95% CI -0.69, 3.17) in favor of modified goniotomy surgery (Fig 2). The change in the
number of glaucoma medication in the PEX cohort was 0.56 ± 0.94 and 0.67 ± 1.28 in the
MIGS and control group respectively. WMD was 0.11 (95% CI -0.53, 0.75) in favor of modified
goniotomy surgery. Similar findings were observed in the POAG cohort where the change in
the number of glaucoma medication was 0.25 ± 0.9 and 1.1 ± 1.1 in the MIGS and control
group respectively. WMD was 0.85 (95% CI 0.54, 1.16) in favor of modified goniotomy surgery
(Fig 3). The study was at serious risk of bias in two domains (S2 Table).
MIGS procedures versus other MIGS procedures. 1 ISTENT versus 2 and 3 ISTENT: in
the RCT by Katz, 38 subjects were implanted with one stent, 41 subjects with two stents, and
40 subjects with three stents. At 12 months, a greater efficacy of 2 versus 1 iStent implantation
has been demonstrated, with mean differences in reduction of 1.90 mmHg (95% CI 1.18–
2.62). Higher IOP reduction resulted after 3 iStent implantation, with mean IOP change from
baseline of 8.2 mmHg compared to 5.4 mmHg after 1 iStent implantation (only results on 1
and 2 iStent are showed in Fig 2). Considering wash-out IOP, the difference in reduction
between 1 and 2 iStent was 1.30 mmHg (95% CI 0.38, 2.22), in favor to 2 iStent. Number of
medication decreased of 1.60 drug/patient in the 1iStent group, 1.64 in the 2 iStent group and
1.43 in the 3 iStent group. This study showed a high risk of performance and detection bias
because of lack of masking (S1 Table).
TRABECTOME versus ISTENT: three studies compared Trabectome to iStent surgery
combined [22, 23, 25]. In these three NRS, 2 iStent were implanted in a total of 108 patients
with POAG and cataract, while Trabectome and phacoemulsification were performed in 113
patients. In the NRS by Gonnermann [22], slightly greater IOP reduction was observed in the
iStent arm (25 eyes), with IOP change of 7.3 ± 4.1 mmHg, compared to 6.7 ± 4.3 mmHg in the
Trabectome arm (25 eyes), WMD = 0.60 (95% CI -1.72, 2.92), Fig 2. Results of number of med-
ication showed greater reduction in the iStent group (0.76 ± 1.06 drug/patient) compared to
the Trabectome group (0.64 ± 1.21), but this was not statistically significant (WMD = 0.12,
95% CI -0.51, 0.75), Fig 3. This study was at serious risk of bias in four domains (S2 Table).
Khan [23] reported that iStent group (49 eyes) achieved greater IOP reduction in compari-
son to the Trabectome group of 52 eyes (5.3 ± 5.3 mmHg vs 3.3 ± 7.9 mmHg respectively)
resulting in 2 mmHg of difference (95% CI -0.60, 4.60), Fig 2. Difference in number of medica-
tion was in favor to iStent procedure, WMD = 0.89 (CI 0.42, 1.36), Fig 3. This study was at seri-
ous risk of bias in three domains (S2 Table).
Kurji [25] reported greater effect in the Trabectome (36 eyes) than in the iStent (34 eyes)
arm: IOP change was respectively 5.1 ± 5.9 mmHg and 3.8 ± 3.9 mmHg, WMD = -1.25 (95%
CI -3.7, 1.2), Fig 2. Number of medication change was respectively 0.49 ± 1.25 drug/patient
and 0.26 ± 0.7 drug/patient, WMD = -0.23 (95% CI -0.72, 0.26), Fig 3. This study was at serious
risk of bias in two domains (S2 Table).
The meta-analysis of these three studies on IOP change, with moderate heterogeneity (I-
square = 24.3%), showed no difference between Trabectome and iStent as combined proce-
dures, WMD = 0.41 (95% CI -1.40, 2.21), p = 0.65. Meta-analysis on the number of medication
was not carried out due to high heterogeneity (I-squared = 73.2%).
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Outcomes in before-after studies
Iop change. Considering all papers as before-after studies (only MIGS arm in the RCT
and NRS), all the MIGS procedures result in a significant reduction of IOP (Fig 4).
The highest reductions was achieved by the study considering naïve patients (WMD = -11.8
in Vold study [41]) followed by studies on Trabectome in PEX subgroups (WMD = -10.60
[26], -9.70 and -9.66 [26, 28]). ELT confirmed the hypotensive efficacy showed in the compara-
tive analysis (WMR = -9 [51] and -8.60 [50] in the RCT and NRS respectively). As regards the
iStent, combined procedures showed a lower IOP reduction compared to solo procedure.
The Hydrus combined study [46] showed a WMD of -2.80 mmHg at one year after surgery,
lower than that observed in the Hydrus as a solo procedure study (WMD = -6.59) [48].
Two years after surgery, overall IOP reduction was similar to that found at one year: WMD
ranged from -1.50 [30] to -11.70 in a wash-out study [43]., although a smaller number of stud-
ies was considered (S1 Fig).
Number of glaucoma medications. Five studies did not report outcomes on the number
of glaucoma medications at one year [38,42,47,50,51].
Four studies reported the number of medications used per protocol [37–40] while one
study reported none glaucoma medication at last follow-up [35].
Finally, one study was conducted on glaucoma naive patients [41].
Thus, Forest plot of the different in change in glaucoma medication reduction comprised a
smaller number of studies (Fig 5).
The XEN [45] as a combined procedure and the iStent [36] as a solo procedure gave the
highest reduction in glaucoma medications compared to before surgery values (WMD = -2.90
and WMD = -1.60 drugs/patient respectively).
Two years after surgery, glaucoma medication reduction was apparently higher compared to
1-year: all WMD, except one, were over 1 drug/patient (S2 Fig). However, the number of papers
available for 2 year-analysis was low (n = 8 [29,30,33,43,46,47,50,51]) and studies with both one and
two-year data did not show glaucoma medication reduction between these timelines [29,30,33,43,
46]. Three studies [47,50,51] provided a medication reduction report at two years only.
Adverse outcomes
Postoperative ocular adverse events are summarized in Table 5.
Adverse events were reported in most studies while some others just reported sentences
like “no serious adverse event were observed”.
There was no report of postoperative infection or BCVA loss > 2 lines due to glaucoma.
The most frequent adverse events were IOP spikes, that occurred in the iStent, in the Cypass
and in the Hydrus both as solo (iStent range 1.1% - 10.1% [39,42]; Cypass 10.8% [44]; Hydrus
4.76% and 6.5% [47,48]) and combined procedures (iStent range 0%-21% [31,29]; Cypass 4.3%
[43]; Hydrus 4% [46]). In the Trabectome and in the ELT, IOP spikes were respectively
reported just for combined (range 5.6%-32.7% [25,23]) or solo procedures (20% [51]).
Additional surgery included trabeculectomy, shunt / valve implant, cyclophotocoagulation,
deep sclerectomy or other MIGS procedures.
Discussion
We have performed a systematic review of the studies comparing MIGS techniques, alone or
combined with cataract surgery, with medical or laser therapy, cataract surgery or other MIGS
techniques.
This paper presents results from studies with three different designs: RCT, NRS and before-
after. One-year results of RCT and NRS have been presented together while before-after
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Fig 4. Forest plot for 12-months IOP reduction (divided by device and procedure).Values expressed in Weighed Mean Difference
(WMD).
https://doi.org/10.1371/journal.pone.0183142.g004
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studies have been reported separately with MIGS arms from both RCT and NRS. In general,
due to the higher intrinsic value of RCT, it’s difficult to compare their results with those from
other study subtypes. However, due to the high number of non RCT papers and the growing
Fig 5. Forest plot for 12-months number of medication reduction (divided by device and procedure). Values expressed in Weighed Mean
Difference (WMD).
https://doi.org/10.1371/journal.pone.0183142.g005
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interest on MIGS, it seemed reasonable to include even NRS and before-after. To avoid as
much as possible biases deriving from low quality series, we applied strict inclusion-exclusion
criteria to NRS and before-after (e.g. patients lost to follow-up > 15%, previous glaucoma sur-
gery). Moreover, meticulous risk of bias assessment has been conducted on all studies, trying
to underline their limits and to inform the scientific community about the necessity of well-
structured, independent RCTs. The reader should be cautious when interpreting the results we
have reported.
Due to the recent introduction of MIGS, we decided to confine our analysis to one-year fol-
low-up data. Nevertheless, two-years analysis of IOP and glaucoma medications, when avail-
able, has been provided in the supplementary matherial. Considering that glaucoma is a
chronic disease, two-year data are somehow limited and longer follow-up data is awaited and
will certainly be available as soon as MIGS become more widely used. The potential effect of
MIGS on subsequent filtering surgery is still to be investigated and any opinion on this matter
can only be speculative.
Efficacy analysis
RCTs. Only nine RCTs were found [30,31,35,36,39,41,43,46,51], three with small sample
sizes (< 100 patients) [31,35,51] on four different MIGS devices (i.e. iStent, Cypass, Hydrus
and ELT).
Five RCTs [30,31,35,43,46] compared MIGS and cataract surgery to cataract surgery alone,
and one study with a small sample size compared ELT with SLT [51], with the MIGS showing
higher IOP and glaucoma medication reduction.
The design of the studies comparing iStent with medical therapy [39,41] was different: in
one study patients with uncontrolled glaucoma on one medication were randomized to either
a combined drug (beta-blocker and prostaglandin) or to the implant of two iStents [39]; the
other study was done in naïve patients randomized to either two iStent or to a prostaglandin
[41]. The implantation of the two iStents obtained a larger reduction of IOP than the compara-
tor group in both studies. Of particular interest is the study on naïve patients in which the
comparator (one prostaglandin) presented a mean reduction in IOP of 11.2 mm Hg corre-
sponding to a 44.6% IOP reduction, somehow more than the 25–35% generally reported in the
literature [54].
One study compared the efficacy of one vs multiple (two or three) iStents implanted in
patients with uncontrolled IOP on two pre-operative medications [36]. Multiple iStents seem
to provide a significant advantage over a single iStent implant.
To avoid the confounding effect of considering at the same time the IOP reduction and the
reduction of medical therapy in three studies comparing cataract surgery with combo surgery
(MIGS and cataract), the patients were washed-out both at baseline and after surgery [31,43,
46]. The iStent [31] and the Cypass [43] studies demonstrated a significant advantage of the
combined surgery over cataract alone, while the Hydrus study [46] demonstrated a modest dif-
ference compared to cataract surgery alone. This interpretation of the results is somehow mis-
leading if the absolute IOP change of the MIGS group and the comparator are not taken into
account. The absolute IOP reduction in the washed-out patients was higher in the Hydrus
study (9.7±4.45 mm Hg) compared to the Cypass (7.9±4.1 mm Hg) and the iStent (1.7± 2.84
mmHg) studies. In the Hydrus study the difference with the comparator was relatively low due
to a greater IOP reduction observed in the comparator group (cataract: 9.2±4.69 mm Hg).
Some of the potential inconsistencies regarding the efficacy of the MIGS procedures when
compared to cataract surgery can thus be due to the variability of IOP reduction in the cataract
surgery group reported in the different studies. The reduction of IOP following cataract
MIGS: A systematic review and meta-analysis
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surgery reported elsewhere in the literature is of approximately 5 mmHg [55]. Some of the dif-
ferences in the IOP reduction after cataract surgery in these studies may be related to the
higher baseline IOP as IOP reduction after cataract surgery has been demonstrated to be pro-
portional to the pre-operative IOP.
The IOP lowering effect of MIGS was greater than that of comparators in all studies,
although statistical significant difference was borderline or not achieved when meta-analysis
was performed. Higher differences were observed in the small ELT vs SLT study by Babighian
(4.1 mmHg) [51] and iStent and cataract surgery vs cataract surgery alone by Fea (3.4 mmHg,
after 12 months washout) [31] and Ferna´ndez-Barrientos (2.8 mmHg) [35]. In RCTs with big-
ger samples the differences between MIGS and their comparators were smaller, between 0.2
[46] and 1.7 mmHg [43]. However, these data should be evaluated considering the coexisting
reduction in glaucoma medication, which was 1.2 [46] and 1.64 [43], thus potentially enlarging
the absolute gap between the MIGS and the control arm.
Unfortunately, estimates on the additive IOP lowering effect of medication are impossible
to perform, due to the different effect on IOP of different molecules and to the inter-subject
variability of response to the medications. Baseline and postoperative wash-out IOP values are
therefore highly recommended.
As a matter of fact it is somehow difficult to provide a systematic comparison between the
different MIGS devices mainly because of the small number of studies reporting both the pre
and post-operative wash-out pressures, but also because of differences in protocols and inclu-
sion criteria.
NRS. Several NRS studies were included in our systematic review: one compared ELT to
medical therapy [50], one Hydrus to SLT [48], three iStent to Trabectome [22,23,25], one Tra-
bectome to trabecular aspiration [24] and one Trabectome to a modified goniotomy technique
[28]. In the ELT, the Hydrus and the Trabectome vs goniotomy studies, the MIGS procedure
were not combined with cataract surgery.
ELT proved to be superior to medical therapy and the Trabectome to trabecular aspiration
both in terms of IOP and medication reduction, whereas the study comparing Hydrus to SLT
demonstrated a similar IOP reduction but a significant advantage in the number of medica-
tions after the implantation of the Hydrus device.
A non significant advantage of the Trabectome over a modified goniotomy technique was
demonstrated in PEX patients only [28]. The comparison of the Trabectome vs 2 iStent proved
either in favour of one method or the other [22,25] but the difference was significant in one
study only, showing a greater reduction of IOP and medications in the iStent group [23].
Our meta-analysis did show an acceptable heterogeneity for the iStent studies (iStent com-
bined vs phacoemulsification; iStent solo vs medical therapy and iStent vs Trabectome com-
bined), whereas were poor in the Trabectome vs modified goniotomy study. There were no
significant differences between the results obtained in the different groups.
Before-after studies. Because of the limited research available on the effect of MIGS, we
also reported on the IOP lowering effect in before/after studies and in the MIGS arm of RCTs
and NRSs, consistently showing an IOP reduction from 1.60 [30] to 11.8 mmHg [41] and a
medication reduction by 0 [26] to 2.9 [45]. Although such information should be interpreted
with caution, since the starting IOP control and measurement setting was not well reported,
these series suggest a potential for IOP lowering by most MIGS and encourage the conduction
of further comparative research using good-quality methods and comparators that are mean-
ingful alternatives in modern glaucoma practice.
Solo versus combined studies. Several studies investigated the efficacy of the MIGS (Tra-
bectome [26–28], iStent [36–42], ELT [50,51], Hydrus [47,48], Cypass [44]) as a solo proce-
dure. All the studies were favorable to MIGS both in term of IOP reduction (-4,57 to -11,80)
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[28,41] and medications reduction (-0.10 to -1.64) [26,36], thus suggesting that the MIGS can
be effective independently from cataract surgery.
The observation that several solo procedures (iStent, Hydrus and ELT) outperformed com-
bined surgery is somehow unexpected because the reduction of IOP achieved by phacoemulsi-
fication alone should add to the effect of the glaucoma procedures [56–58]. This difference is
particularly evident when considering the iStent because of the larger number of studies and
could not be attributed to either the implantation of different iStent models not to the implan-
tation of multiple devices. Most of the solo iStent studies were performed later and a possible
explanation of their apparent better performance could lie in improved surgical techniques
and more appropriate selection criteria. Some of the later iStent studies have been performed
in areas where the access to pharmacological treatment may be difficult and those patients
may have been less exposed to potential negative effect of prolonged topical therapy.
Although the potential negative effect of the prolonged use of glaucoma medications on the
results of MIGS device has never been hypothesized, this has been demonstrated with other
laser [59] and surgical procedures [60].
Safety
The number of complications is missing in some of the studies [26,41], but it is minimal when-
ever reported. In particular there were no reports of infection or decrease in Best Corrected
Visual Acuity (BCVA). IOP spikes incidence ranged from 0 to 32.7% [28,31 and 23]. Revision
of the procedure was relatively low for the iStent (0 to 6.89%) [29,31 and 32] and more com-
mon following the XEN implantation (23.3%) [45], which relies on the presence of a conjunc-
tival bleb. Additional surgery was done in less than 10% of patients with the exception of the
Cypass (18.5%) [44] and the ELT (10.9%) [49].
Risk of bias
Considering the RCT studies, some methodological issues deserve discussion. In most of the
studies a clear definition of the randomization method is lacking. The masking of most RCT
has been judged as unclear, but it should be pointed out that masking a surgical procedure can
be almost impossible both to the patient and to the examiner due to the fact that the device can
sometimes be clearly visible. IOP should ideally be recorded by a masked technician or with a
two-person system.
Because of the limited amount of evidence, we expanded our analysis by presenting uncon-
trolled before/after series as well as data from the MIGS arm of NRS and RCTs to yield a better
picture of the knowledge in this field.
We adopted ROBINS-I [16], a recently developed methodological tool, to assess the risk
of bias in NRS as well as in uncontrolled before/after studies. However, we caution readers
regarding the fact that the use of ROBINS-I to assess before/after series is not validated
and should be considered experimental unless a specific version is made available by the
developers.
When assessing the methodological quality of non-randomized studies, we paid particular
attention to specific issues, which apply to both NRS and uncontrolled before/after studies.
First, IOP measurement should have been carefully collected, ideally by personnel unaware of
the treatment status and not by the treating physician; a minimum of three IOP measurement
or a diurnal curve at the before and after point would be useful to limit random error or regres-
sion to the mean. Furthermore, in the studies it should be clearly stated if the patients were
consecutive, how many patients were excluded during the study and what was the reason for
exclusion and how many patients were lost to follow-up.
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To minimize the reciprocal effect of IOP reduction and medical therapy reduction, wash-
out is advisable and if not deemed possible a staged re-introduction of medical therapy would
be advisable. Following predefined rules, it would be clear, then, that a single therapy would
correspond to a certain compound and that the addition of a second medication would corre-
spond to another definite compound.
Unfortunately, in most NRS and before/after studies the Authors failed to provide details
suggesting that such high standards were met. Conflict of interest is believed to be a potential
source of bias in clinical studies, including RCTs. It should be noted that several studies are
sponsored and this applies to both RCT, NRS and before-after studies. Detailed funding by
device industry or authors affiliations are reported (S4 Table). In general, larger studies need
some kind of sponsorship as it happens to all multicentric drug studies. Considering the inde-
pendent studies, it should be noted that some may have benefitted from the free use of the
device, which again is common in the pharmaceutical trials, where the cost of the drug is nev-
ertheless incomparable to the price of this kind of devices.
Conclusions
A strength of our review was the inclusion of all available evidence on MIGS techniques, com-
prising RCTs and NRS and assessing their methodological quality.
Our systematic review has found that, although there is increasing interest on safer, stan-
dardized and minimally invasive surgeries, the evidence on the efficacy of MIGS compared to
other therapies is still limited and is based on few RCTs of acceptable quality and a larger num-
ber of NRS and uncontrolled before/after series.
We suggest that future research should be comparative, ideally randomized, including
patients and alternative treatments that are relevant to clinical settings.
The results of this meta-analysis show a decrease of IOP and a reduction of glaucoma medi-
cations after MIGS surgery with a low complication rate. This could be potentially very rele-
vant for patients and health care providers, allowing a significant number of POAG patients to
reduce their glaucoma medication burden. The remarkable heterogeneity of the studies on this
topic suggests the need for additional research to understand how to maximize the utility of
these new procedures. The potential influence of prolonged glaucoma medication treatment,
as well as the effects of higher pre-operative IOP, patient selection and surgical performances
should be examined in future investigations.
Similarly, the impact of these mini-invasive procedures on the reported quality of life of
patients and their costs, potentially influencing their diffusion, should be investigated.
Supporting information
S1 Appendix. Search strategy for Medline.
(DOCX)
S2 Appendix. References of studies excluded on the basis of full text.
(DOCX)
S1 Table. Risk of bias summary for RCTs: Review authors’ judgements about each risk of
bias item for each included study.
(DOCX)
S2 Table. Risk of bias summary for non-RCTs NRS: Review authors’ judgements about
each risk of bias item for each included study.
(DOCX)
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 28 / 33
S3 Table. Risk of bias summary for non-RCTs Before-after studies: Review authors’ judge-
ments about each risk of bias item for each included study.
(DOCX)
S4 Table. Risk of bias sponsor-related for all studies.
(DOCX)
S1 Fig. Risk of bias summary for RCTs: Review authors’ judgements about each risk of
bias item for each included study.
(DOCX)
S2 Fig. Methodological quality graph for RCTs: Review authors’ judgements about each
methodological quality item presented as percentages across all included RCTs.
(DOCX)
S3 Fig. Methodological quality graph for non-RCTs (NRS): Review authors’ judgements
about each methodological quality item of ROBINS-I presented as percentages across all
included RCTs.
(DOCX)
S4 Fig. Methodological quality graph for non-RCTs (Before-after study): Review authors’
judgements about each methodological quality item of ROBINS-I presented as percentages
across all included RCTs.
(DOCX)
S5 Fig. Forest plot for 24-months IOP reduction. Values expressed in Weighed Mean Differ-
ence (WMD).
(DOCX)
S6 Fig. Forest plot for 24-months glaucoma medication reduction. Values expressed in
Weighed Mean Difference (WMD).
(DOCX)
S7 Fig. PRISMA checklist.
(DOCX)
Acknowledgments
We thank Giovannino Ciccone for providing methodological perspective and Chiara Mona-
gheddu for designing the search strategy.
All authors have no known conflicts of interest.
Author Contributions
Conceptualization: Antonio Maria Fea.
Data curation: Carlo Lavia, Laura Dallorto, Milena Maule, Manuela Ceccarelli.
Formal analysis: Carlo Lavia, Laura Dallorto, Milena Maule.
Methodology: Carlo Lavia, Laura Dallorto, Milena Maule, Manuela Ceccarelli.
Resources: Manuela Ceccarelli.
Supervision: Milena Maule, Manuela Ceccarelli, Antonio Maria Fea.
Validation: Milena Maule.
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 29 / 33
Writing – original draft: Carlo Lavia, Laura Dallorto, Antonio Maria Fea.
Writing – review & editing: Carlo Lavia, Laura Dallorto, Antonio Maria Fea.
References
1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J
Ophthalmol. 2006; 90(3):262–267. https://doi.org/10.1136/bjo.2005.081224 PMID: 16488940
2. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition. Savona, Italy.
Editrice PubliComm, 2014.
3. Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K et al. The Most Common
Barriers to Glaucoma Medication Adherence: A Cross-Sectional Surv Ophthalmol. 2015; 122(7):1308–
1316.
4. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;
53 Suppl1:S57–68.
5. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use.
Clin Ther. 2000; 22(2):167–208. https://doi.org/10.1016/S0149-2918(00)88478-7 PMID: 10743979
6. Dreer LE, Girkin C, Mansberger SL. Determinants of medication adherence to topical glaucoma ther-
apy. J Glaucoma. 2012; 21(4):234–240. https://doi.org/10.1097/IJG.0b013e31821dac86 PMID:
21623223
7. Gedde SJ, Singh K, Schiffman JC, Feuer WJ. Tube Versus Trabeculectomy Study Group. The Tube
Versus Trabeculectomy Study: interpretation of results and application to clinical practice. Curr Opin
Ophthalmol. 2012; 23(2):118–126. https://doi.org/10.1097/ICU.0b013e32834ff2d1 PMID: 22249235
8. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Tube versus Trabeculect-
omy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) Study after five
years of follow-up. Am J Ophthalmol. 2012; 153(5):789–803. https://doi.org/10.1016/j.ajo.2011.10.026
PMID: 22245458
9. Francis BA, Singh K, Lin SC, Hodapp E, Jampel HD, Samples JR et al. Novel glaucoma procedures: a
report by the American Academy of Ophthalmology. Ophthalmology. 2011; 118(7):1466–1480. https://
doi.org/10.1016/j.ophtha.2011.03.028 PMID: 21724045
10. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr
Opin Ophthalmol. 2012; 23(2):96–104. https://doi.org/10.1097/ICU.0b013e32834ff1e7 PMID:
22249233
11. Caprioli J, Kim JH, Friedman DS, Kiang T, Moster MR, Parrish RK 2nd et al. Special Commentary: Sup-
porting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery: Summary of a Joint
Meeting of the American Glaucoma Society and the Food and Drug Administration, Washington, DC,
February 26, 2014. Ophthalmology. 2015; 122(9):1795–1801. https://doi.org/10.1016/j.ophtha.2015.
02.029 PMID: 25881513
12. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects.
Clin Ophthalmol. 2016; 10:189–206. https://doi.org/10.2147/OPTH.S80490 PMID: 26869753
13. Brandão LM, Grieshaber MC. Update on Minimally Invasive Glaucoma Surgery (MIGS) and New
Implants. J Ophthalmol. 2013; 2013:705915. https://doi.org/10.1155/2013/705915 PMID: 24369494
14. Manasses DT, Au L. The New Era of Glaucoma Micro-stent Surgery. Ophthalmol Ther. 2016; 5(2):135–
146. https://doi.org/10.1007/s40123-016-0054-6 PMID: 27314234
15. Higgins JPT, Altman DG (editors). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
16. Sterne JA, Herna´n MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al. ROBINS-I: a tool for
assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. https://doi.org/
10.1136/bmj.i4919 PMID: 27733354
17. Friedrich JO, Adhikari NK, Beyene J. The ratio of means method as an alternative to mean differences
for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Metho-
dol. 2008; 8:32. https://doi.org/10.1186/1471-2288-8-32 PMID: 18492289
18. Higgins JP, White IR and Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported
on log-transformed or raw scales. Stat Med 2008; 27:6072–6092. https://doi.org/10.1002/sim.3427
PMID: 18800342
19. Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is
more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016; 70:129–
135. https://doi.org/10.1016/j.jclinepi.2015.09.005 PMID: 26386323
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 30 / 33
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
test. BMJ 1997; 315:629–634. PMID: 9310563
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Bio-
metrics 1994; 50(4):1088–1101. PMID: 7786990
22. Gonnermann J, Bertelmann E, Pahlitzsch M, Maier AK, Torun N, Klamann MK. Contralateral eye com-
parison study in MICS & MIGS: Trabectome® vs. iStent inject®. Graefes Arch Clin Exp Ophthalmol.
2017; 255(2):359–365. https://doi.org/10.1007/s00417-016-3514-8 PMID: 27815624
23. Khan M, Saheb H, Neelakantan A, Fellman R, Vest Z, Harasymowycz P, et al. Efficacy and safety of
combined cataract surgery with 2 trabecular microbypass stents versus ab interno trabeculotomy. J
Cataract Refract Surg. 2015; 41(8):1716–1724. https://doi.org/10.1016/j.jcrs.2014.12.061 PMID:
26432130
24. Klamann MK, Gonnermann J, Maier AK, Ruokonen PC, Torun N, Joussen AM, et al. Combined clear
cornea phacoemulsification in the treatment of pseudoexfoliative glaucoma associated with cataract:
significance of trabecular aspiration and ab interno trabeculectomy. Graefes Arch Clin Exp Ophthalmol.
2013; 251(9):2195–2199. https://doi.org/10.1007/s00417-013-2408-2 PMID: 23812010
25. Kurji K, Rudnisky CJ, Rayat JS, Arora S, Sandhu S, Damji KF, et al. Phaco-trabectome versus phaco-
iStent in patients with open-angle glaucoma. Can J Ophthalmol. 2017; 52(1):99–106. https://doi.org/10.
1016/j.jcjo.2016.06.018 PMID: 28237158
26. Pahlitzsch M, Gonnermann J, Maier AK, Torun N, Bertelmann E, Joussen AM, et al. Trabeculectomy
Ab Interno in Primary Open Angle Glaucoma and Exfoliative Glaucoma. Klin Monbl Augenheilkd. 2015;
232(10):1198–1207. https://doi.org/10.1055/s-0041-105941 PMID: 26512851
27. Ting JL, Damji KF, Stiles MC. Trabectome Study Group. Ab interno trabeculectomy: outcomes in exfoli-
ation versus primary open-angle glaucoma. J Cataract Refract Surg. 2012; 38(2):315–323. https://doi.
org/10.1016/j.jcrs.2011.08.043 PMID: 22322166
28. Pahlitzsch M, Gonnermann J, Maier AK, Bertelmann E, Klamann MK, Erb C. Modified goniotomy as an
alternative to trabectome in primary open angle glaucoma and pseudoexfoliation glaucoma: 1 year
results. Can J Ophthalmol. 2017; 52(1):92–98. https://doi.org/10.1016/j.jcjo.2016.07.011 PMID:
28237157
29. Arriola-Villalobos P, Martı´nez-de-la-Casa JM, Dı´az-Valle D, Ferna´ndez-Pe´rez C, GarcI´a-Sa´nchez J,
Garcı´a-Feijoo´ J. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification
for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012; 96
(5):645–649. https://doi.org/10.1136/bjophthalmol-2011-300218 PMID: 22275344
30. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. iStent Study Group. Cataract surgery with trabecular
micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract:
two-year follow-up. J Cataract Refract Surg. 2012; 38(8):1339–1345. https://doi.org/10.1016/j.jcrs.
2012.03.025 PMID: 22814041
31. Fea AM, Consolandi G, Zola M, Pignata G, Cannizzo P, Lavia C, et al. Micro-Bypass Implantation for
Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up. J Ophthalmol.
2015; 2015:795357. https://doi.org/10.1155/2015/795357 PMID: 26587282
32. Spiegel D, Wetzel W, Neuhann T, Stuermer J, Hoeh H, Garcia-Feijoo J, et al. Coexistent primary open-
angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cata-
ract surgery. Eur J Ophthalmol. 2009; 19(3):393–399. PMID: 19396784
33. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, Morales-Fernandez L, Fernandez-Perez C,
Garcia-Feijoo J. Glaukos iStent inject® Trabecular Micro-Bypass Implantation Associated with Cataract
Surgery in Patients with Coexisting Cataract and Open-Angle Glaucoma or Ocular Hypertension: A
Long-Term Study. J Ophthalmol. 2016; 2016:1056573. https://doi.org/10.1155/2016/1056573 PMID:
27882243
34. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in
cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012; 38(11):1911–1917.
https://doi.org/10.1016/j.jcrs.2012.07.017 PMID: 22980724
35. Ferna´ndez-Barrientos Y, Garcı´a-Feijoo´ J, Martı´nez-de-la-Casa JM, Pablo LE, Ferna´ndez-Pe´rez C,
Garcı´a Sa´nchez J. Fluorophotometric study of the effect of the glaukos trabecular microbypass stent on
aqueous humor dynamics. Invest Ophthalmol Vis Sci. 2010; 51(7):3327–3332. https://doi.org/10.1167/
iovs.09-3972 PMID: 20207977
36. Katz LJ, Erb C, Carceller GA, Fea AM, Voskanyan L, Wells JM, et al. Prospective, randomized study of
one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive
medication. Clin Ophthalmol. 2015; 9:2313–2320. https://doi.org/10.2147/OPTH.S96695 PMID:
26715834
37. Ahmed II, Katz LJ, Chang DF, Donnenfeld ED, Solomon KD, Voskanyan L, et al. Prospective evaluation
of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 31 / 33
glaucoma. J Cataract Refract Surg. 2014; 40(8):1295–1300. https://doi.org/10.1016/j.jcrs.2014.07.004
PMID: 25088627
38. Donnenfeld ED, Solomon KD, Voskanyan L, Chang DF, Samuelson TW, Ahmed II, et al. A prospective
3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clin
Ophthalmol. 2015; 9:2057–2065. https://doi.org/10.2147/OPTH.S91732 PMID: 26604675
39. Fea AM, Belda JI, Rękas M, Ju¨nemann A, Chang L, Pablo L, et al. Prospective unmasked randomized
evaluation of the iStent inject (®) versus two ocular hypotensive agents in patients with primary open-
angle glaucoma. Clin Ophthalmol. 2014; 8:875–882. https://doi.org/10.2147/OPTH.S59932 PMID:
24855336
40. Lindstrom R, Lewis R, Hornbeak DM, Voskanyan L, Giamporcaro JE, Hovanesian J, et al. Outcomes
Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with
Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. Adv Ther. 2016; 33(11):2082–2090.
https://doi.org/10.1007/s12325-016-0420-8 PMID: 27739003
41. Vold SD, Voskanyan L, Tetz M, Auffarth G, Masood I, Au L, et al. Newly Diagnosed Primary Open-
Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36
Months. Ophthalmol Ther. 2016; 5(2):161–172. https://doi.org/10.1007/s40123-016-0065-3 PMID:
27619225
42. Voskanyan L, Garcı´a-Feijoo´ J, Belda JI, Fea A, Ju¨nemann A, Baudouin C. Synergy Study Group. Pro-
spective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. Adv
Ther. 2014; 31(2):189–201. https://doi.org/10.1007/s12325-014-0095-y PMID: 24452726
43. Vold S, Ahmed II, Craven ER, Mattox C, Stamper R, Packer M, et al. Two-Year COMPASS Trial
Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma
and Cataracts. Ophthalmology. 2016; 123(10):2103–2112. https://doi.org/10.1016/j.ophtha.2016.06.
032 PMID: 27506486
44. Garcı´a-Feijoo J, Rau M, Grisanti S, Grisanti S, Ho¨h H, Erb C, et al. Supraciliary Micro-stent Implantation
for Open-Angle Glaucoma Failing Topical Therapy: 1-Year Results of a Multicenter Study. Am J
Ophthalmol. 2015; 159(6):1075–1081. https://doi.org/10.1016/j.ajo.2015.02.018 PMID: 25747677
45. Pe´rez-Torregrosa VT, Olate-Pe´rez A´ , Cerdà-Iba´ñez M, Gargallo-Benedicto A, Osorio-Alayo V, Bar-
reiro-Rego A, et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2
incisions. Arch Soc Esp Oftalmol. 2016; 91(9):415–21 https://doi.org/10.1016/j.oftal.2016.02.006
PMID: 26995503
46. Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, Larrosa JM, Fea A, Lemij H, et al. A Randomized
Trial of a Schlemm’s Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in
Open-Angle Glaucoma. Ophthalmology. 2015; 122(7):1283–1293. https://doi.org/10.1016/j.ophtha.
2015.03.031 PMID: 25972254
47. Gandolfi SA, Ungaro N, Ghirardini S, Tardini MG, Mora P. Comparison of Surgical Outcomes between
Canaloplasty and Schlemm’s Canal Scaffold at 24 Months’ Follow-Up. J Ophthalmol. 2016;
2016:3410469. https://doi.org/10.1155/2016/3410469 PMID: 26989497
48. Fea AM, Ahmed II, Lavia C, Mittica P, Consolandi G, Motolese I, et al. Hydrus microstent compared to
selective laser trabeculoplasty in primary open angle glaucoma: one year results. Clin Exp Ophthalmol.
2017; 45(2):120–127. https://doi.org/10.1111/ceo.12805 PMID: 27449488
49. To¨teberg-Harms M, Hanson JV, Funk J. Cataract surgery combined with excimer laser trabeculotomy
to lower intraocular pressure: effectiveness dependent on preoperative IOP. BMC Ophthalmol. 2013;
13:24. https://doi.org/10.1186/1471-2415-13-24 PMID: 23799932
50. Babighian S, Rapizzi E, Galan A. Efficacy and safety of ab interno excimer laser trabeculotomy in pri-
mary open-angle glaucoma: two years of follow-up. Ophthalmologica. 2006; 220(5):285–290. https://
doi.org/10.1159/000094616 PMID: 16954703
51. Babighian S, Caretti L, Tavolato M, Cian R, Galan A. Excimer laser trabeculotomy vs 180 degrees
selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial.
Eye (Lond). 2010; 24(4):632–638.
52. Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE. US iStent Study Group. Randomized
evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and
cataract. Ophthalmology. 2011; 118(3):459–467. https://doi.org/10.1016/j.ophtha.2010.07.007 PMID:
20828829
53. Arriola-Villalobos P, Martı´nez-de-la-Casa JM, Dı´az-Valle D, Garcı´a-Vidal SE, Ferna´ndez-Pe´rez C, Gar-
cı´a-Sa´nchez J, et al. Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexis-
tent open-angle glaucoma or ocular hypertension and cataract. Br J Ophthalmol. 2013 Oct; 97
(10):1250–5 https://doi.org/10.1136/bjophthalmol-2012-302394 PMID: 23603758
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 32 / 33
54. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and
travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator
multicenter study. Am J Ophthalmol. 2003; 135(5):688–703. PMID: 12719078
55. Poley BJ, Lindstrom RL, Samuelson TW, Schulze R Jr. Intraocular pressure reduction after phacoemul-
sification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes: evaluation of
a causal relationship between the natural lens and open-angle glaucoma. J Cataract Refract Surg.
2009; 35(11):1946–55. https://doi.org/10.1016/j.jcrs.2009.05.061 PMID: 19878828
56. Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol.
2010; 21(2):118–122. https://doi.org/10.1097/ICU.0b013e3283360ac3 PMID: 20040874
57. Melancia D, Abegão Pinto L, Marques-Neves C. Cataract surgery and intraocular pressure. Ophthalmic
Res. 2015; 53(3):141–148. https://doi.org/10.1159/000377635 PMID: 25765255
58. Fogagnolo P, Centofanti M, Figus M, Frezzotti P, Fea A, Ligorio P, et al. Short-term changes in intraocu-
lar pressure after phacoemulsification in glaucoma patients. Ophthalmologica. 2012; 228(3):154–158.
https://doi.org/10.1159/000337838 PMID: 22572718
59. Fea A.M., Dorin G. Laser treatment of glaucoma: Evolution of laser trabeculoplasty techniques. 2008; 6
(2):45–52
60. Baudouin C, Labbe´ A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the
bad and the ugly. Prog Retin Eye Res. 2010; 29(4):312–334. https://doi.org/10.1016/j.preteyeres.2010.
03.001 PMID: 20302969
MIGS: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183142 August 29, 2017 33 / 33
